Loading...
XJPX4534
Market cap742mUSD
Jan 17, Last price  
3,275.00JPY
1D
0.77%
1Q
-7.36%
Jan 2017
-19.24%
Name

Mochida Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4534 chart
P/E
25.53
P/S
1.13
EPS
128.26
Div Yield, %
2.44%
Shrs. gr., 5y
-1.98%
Rev. gr., 5y
-1.27%
Revenues
102.89b
-0.36%
68,025,000,00070,640,000,00074,070,000,00074,593,000,00075,167,000,00078,548,000,00079,325,000,00086,196,000,00089,230,000,00093,953,000,00087,261,000,00092,274,000,00097,353,000,000106,749,000,000109,652,000,000101,801,000,000102,995,000,000110,179,000,000103,261,000,000102,885,000,000
Net income
4.55b
-31.61%
2,299,000,0004,988,000,0006,030,000,0008,387,000,0008,754,000,0009,869,000,0005,333,000,0009,076,000,0009,152,000,0009,892,000,0007,544,000,0008,150,000,0008,526,000,0009,023,000,0008,435,000,0004,598,000,0008,587,000,00010,569,000,0006,649,000,0004,547,000,000
CFO
-7.48b
L
6,133,000,0008,446,000,0006,951,000,0005,585,000,00010,608,000,00012,217,000,0007,061,000,0008,706,000,00011,909,000,00012,478,000,0005,122,000,00015,211,000,0005,583,000,0003,283,000,00012,565,000,0009,347,000,0009,198,000,0007,459,000,0007,297,000,000-7,480,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 03, 2025

Profile

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
URL
https://www.mochida.co.jp/
IPO date
May 13, 1963
Employees
1,529
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
102,885,000
-0.36%
103,261,000
-6.28%
110,179,000
6.98%
Cost of revenue
97,082,000
94,753,000
95,787,000
Unusual Expense (Income)
NOPBT
5,803,000
8,508,000
14,392,000
NOPBT Margin
5.64%
8.24%
13.06%
Operating Taxes
1,613,000
2,395,000
4,022,000
Tax Rate
27.80%
28.15%
27.95%
NOPAT
4,190,000
6,113,000
10,370,000
Net income
4,547,000
-31.61%
6,649,000
-37.09%
10,569,000
23.08%
Dividends
(2,887,000)
(3,372,000)
(3,445,000)
Dividend yield
2.50%
2.72%
2.42%
Proceeds from repurchase of equity
(3,492,000)
(3,512,000)
(2,511,000)
BB yield
3.02%
2.83%
1.76%
Debt
Debt current
12,000
Long-term debt
686,000
178,000
Deferred revenue
Other long-term liabilities
916,000
2,595,000
1,851,000
Net debt
(69,272,000)
(82,041,000)
(84,672,000)
Cash flow
Cash from operating activities
(7,480,000)
7,297,000
7,459,000
CAPEX
(2,296,000)
(2,166,000)
(3,096,000)
Cash from investing activities
74,000
(2,949,000)
(2,007,000)
Cash from financing activities
(6,393,000)
(6,884,000)
(5,956,000)
FCF
(11,404,000)
5,646,000
6,060,000
Balance
Cash
46,789,000
60,509,000
61,914,000
Long term investments
23,169,000
21,722,000
22,758,000
Excess cash
64,813,750
77,067,950
79,163,050
Stockholders' equity
124,251,000
252,945,000
257,540,000
Invested Capital
64,413,250
51,811,050
49,678,950
ROIC
7.21%
12.05%
22.44%
ROCE
4.37%
6.49%
10.93%
EV
Common stock shares outstanding
35,863
37,160
38,102
Price
3,220.00
-3.59%
3,340.00
-10.58%
3,735.00
-12.94%
Market cap
115,478,860
-6.96%
124,114,400
-12.79%
142,310,970
-14.13%
EV
46,206,860
163,002,400
178,789,970
EBITDA
8,611,000
11,180,000
17,081,000
EV/EBITDA
5.37
14.58
10.47
Interest
2,000
2,000
Interest/NOPBT
0.03%
0.01%